Developing a Bioluminescent Mouse Model for CAR T Cell Therapy in AML
Author Information
Author(s): Safont Mireia Mayoral, Leitch Calum, Popa Mihaela, Gjerstad May Eriksen, Caulier Benjamin, Inderberg Else Marit, Wälchli Sébastien, Gelebart Pascal, Cormack Emmet Mc
Primary Institution: University of Bergen
Hypothesis
Can a bioluminescent AML-PDX mouse model be developed to evaluate CAR T cell therapy?
Conclusion
The protocol successfully outlines the development of a bioluminescent AML-PDX model for evaluating CAR T cell therapy.
Supporting Evidence
- Patient-derived xenograft models capture the complexity of patient samples.
- The protocol details procedures for validating the AML-PDX model.
- Bioluminescent imaging allows for non-invasive monitoring of leukemia progression.
- The model can be used to evaluate various immunotherapeutic approaches.
Takeaway
This study shows how to create a special mouse model that glows to help scientists test new cancer treatments.
Methodology
The protocol includes steps for transducing, engrafting, expanding, and enriching AML-PDX cells, followed by in vitro and in vivo validation.
Limitations
The model requires immunodeficient mice, which may not fully represent the human immune system, potentially affecting findings.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website